IS5117A - Use of 1-(4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyrid-1-yl)-2-(6,7-dimethoxynapht-2-yl)ethane for preparing medicines for the treatment of cerebral and neuronal disorders - Google Patents

Use of 1-(4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyrid-1-yl)-2-(6,7-dimethoxynapht-2-yl)ethane for preparing medicines for the treatment of cerebral and neuronal disorders

Info

Publication number
IS5117A
IS5117A IS5117A IS5117A IS5117A IS 5117 A IS5117 A IS 5117A IS 5117 A IS5117 A IS 5117A IS 5117 A IS5117 A IS 5117A IS 5117 A IS5117 A IS 5117A
Authority
IS
Iceland
Prior art keywords
dimethoxynapht
tetrahydropyrid
trifluoromethylphenyl
cerebral
ethane
Prior art date
Application number
IS5117A
Other languages
English (en)
Icelandic (is)
Inventor
Croci Tiziano
Fournier Jacqueline
Guzzi Umberto
Palmieri Costantino
Original Assignee
Sanofi-Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Synthelabo filed Critical Sanofi-Synthelabo
Publication of IS5117A publication Critical patent/IS5117A/is

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
IS5117A 1997-02-03 1999-07-15 Use of 1-(4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyrid-1-yl)-2-(6,7-dimethoxynapht-2-yl)ethane for preparing medicines for the treatment of cerebral and neuronal disorders IS5117A (is)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/FR1997/000202 WO1998033502A1 (fr) 1997-02-03 1997-02-03 Utilisation du 1-[4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyrid-1yl]-2-(6,7-dimethoxynapht-2-yl)ethane pour la preparation de medicaments destines aux traitements de troubles cerebraux et neuronaux

Publications (1)

Publication Number Publication Date
IS5117A true IS5117A (is) 1999-07-15

Family

ID=9502506

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5117A IS5117A (is) 1997-02-03 1999-07-15 Use of 1-(4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyrid-1-yl)-2-(6,7-dimethoxynapht-2-yl)ethane for preparing medicines for the treatment of cerebral and neuronal disorders

Country Status (11)

Country Link
EP (1) EP0954311A1 (cs)
JP (1) JP2001511141A (cs)
AU (1) AU1607397A (cs)
CA (1) CA2279326A1 (cs)
CZ (1) CZ275399A3 (cs)
EE (1) EE9900332A (cs)
HU (1) HUP0000767A3 (cs)
IL (1) IL130994A0 (cs)
IS (1) IS5117A (cs)
TR (1) TR199901722T2 (cs)
WO (1) WO1998033502A1 (cs)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6272180B1 (en) * 1997-11-21 2001-08-07 Sharp Laboratories Of America, Inc. Compression and decompression of reference frames in a video decoder

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2662355B1 (fr) * 1990-05-22 1994-11-10 Sanofi Sa Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux.
US5618822A (en) * 1990-05-23 1997-04-08 Sanofi N-substituted trifluoromethylphenyltetrahydropyridines, process for the preparation thereof, intermediates in said process and pharmaceutical compositions containing them
FR2662442A1 (fr) * 1990-05-23 1991-11-29 Midy Spa Trifluoromethylphenyltetrahydropyridines n-substituees procede pour leur preparation, intermediaires du procede et compositions pharmaceutiques les contenant.

Also Published As

Publication number Publication date
EP0954311A1 (fr) 1999-11-10
CZ275399A3 (cs) 1999-12-15
IL130994A0 (en) 2001-01-28
CA2279326A1 (fr) 1998-08-06
EE9900332A (et) 2000-02-15
AU1607397A (en) 1998-08-25
WO1998033502A1 (fr) 1998-08-06
TR199901722T2 (xx) 2000-08-21
HUP0000767A3 (en) 2000-10-30
JP2001511141A (ja) 2001-08-07
HUP0000767A2 (hu) 2000-09-28

Similar Documents

Publication Publication Date Title
EE200200274A (et) Pürrolidiinatseetamiidi derivaadi kasutamine ravimi valmistamiseks, mis on ette nähtud kesknärvisüsteemi häirete ravimiseks, ja farmatseutiline kompositsioon
NO20004915L (no) Transdermalt terapeutisk system som inneholder en D2-agonist og som tilveiebringes for behandling av Parkinsons sykdom og en fremgangsmÕte for dets fremstilling
EE200200442A (et) Piperasiini ja piperidiini derivaadid neuronaalsete kahjustuste raviks
NO20003288D0 (no) Preparat for behandling av respiratoriske sykdommer og hudsykdommer, omfattende minst en leukotrienantagonist og minst ett antihistamin
FI20000720A7 (fi) Pitkitettyyn vapautumiseen perustuva tablettiformulaatio Parkisonin taudin hoitamiseksi
CY2013041I1 (el) Φαρμακευτικες συνθεσεις περιλαμβανοντας δεξτρομεθορφανη και κινιδινη για την αγωγη νευρολογικων διαταραχων
DK629989D0 (da) Oralt, antiseptisk middel, dets fremstilling og anvendelse samt produkter, hvori det indgaar
FI971566L (fi) Kompakti lääkeannostelija sisäänhengitettävien lääkepartikkelien generoimiseksi
DK0979079T3 (da) Anvendelse af tetrahydropyridinderivater til fremstilling af lægemidler til behandling af sygdomme, der medförer en demyelinisering
ES2159362T3 (es) Utilizacion de la 1-(2-naft-2-iletil)-4-(3-trifluorometilfenil)-1,2,3,6-tetrahidropiridina para la preparacion de medicamentos destinados para el tratamiento de la esclerosis lateral amiotrofica.
NZ502495A (en) Use of a specific antagonist of 5HT2 receptor antagonist for the preparation of medicines useful in the treatment of sleep apnoea syndrome
HUP0204050A3 (en) Drug combination for the treatment of depression and related disorders comprising mirtazapine and gepirone
NO306060B1 (no) Substituerte kanelsyreguanidider, deres anvendelse samt medikamenter inneholdende guanididene
SE9903995D0 (sv) New combination
EE200100553A (et) Saredutandi ja selle farmatseutiliselt vastuvõetavate soolade kasutamine meeleoluhäirete, kohanemishäirete või segatüüpi ärev-depressiivsete häirete raviks või vältimiseks kasulike ravimite valmistamiseks
IS5117A (is) Use of 1-(4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyrid-1-yl)-2-(6,7-dimethoxynapht-2-yl)ethane for preparing medicines for the treatment of cerebral and neuronal disorders
NO973531D0 (no) Anvendelse av melatonin for behandling av pasienter som lider av medikamentavhengighet
BR0008703A (pt) Utilização da tianeptina para a obtenção de medicamentos destinados ao tratamento das patologias da neurodegenerescência
FI950725A7 (fi) Trisyklisen yhdisteen käyttö muistin ja tajunnan häiriöiden hoitoon tarkoitettujen lääkevalmisteiden valmistukseen
NZ508325A (en) Microemulsion preconcentrates for oral administration containing a piperidine substance P antagonist
NO993728D0 (no) Anvendelse av 1-[4-(3-trifluormeylfenyl)-1,2,3,6-tetrahydropyrid-1yl]-2-(6,7-dimetoksynaft-2yl)etan for fremstilling av medikamenter for behandling av cerebrale og nevronale forstyrrelser
FI953622A7 (fi) Ifenprodiilin ja sen diastereoisomeerien käyttö lääkeaineiden valmistukseen, jotka lääkeaineet ovat käyttökelpoisia perifeeristen neuropatiatilojen ja keskushermoston degeneratiivisten sairauksien hoitoon
BR9714486A (pt) Utilização de 1-[4-(3-trifluorometilfenil)- 1,2,3,6-tetra-hidropirid-1-il]-2-(6,7-dimetoxinaft-2-il) etano
ITTO971062A0 (it) Farmaco per la cura dell'ircismo contenente un adrenocorticosteroide.
ZA921101B (en) Use of tetra: Hydro-thieno-pyrido-indole derivatives for the prepartion of a medicine for the treatment of skin disorders.